By 12 April, 2021 - 12:42pm 6 views
British-Swedish pharmacist AstraZeneca announced that its diabetes drug Farxiga is not effective in treating COVID- 19 patients, according to the first results of its clinical trials.
© Provided by Millennium AstraZeneca's trial was conducted in 1,000 250 people. (Reuters)
Farxiga's trial "did not reach a sufficient statistical level" to prevent mortality, the laboratory said in a statement.
These are the first results of a phase 3 clinical trial conducted with 1,250 people, in collaboration with the American institute specialized in cardiovascular diseases Saint Luke's Mid America.
The objective of the study was to evaluate the efficacy of Farxiga in hospitalized patients with covid-19 and at risk of developing complications , in particular those who already have other pathologies such as hypertension, diabetes or heart or kidney disease. Full trial results are due to be released in May.
This adds a further setback for AstraZeneca, whose COVID-19 vaccine has raised many questions , especially regarding potential side effects such as blood clots. blood.
Video: Cofepris authorizes emergency use of Covaxin vaccine from India (Dailymotion)
Some countries have stopped using it and others have set age limits . For example, in the United Kingdom, where more than 20 million doses have been administered so far, it was reserved primarily for those over 30.
Deliveries of orders from different countries were also affected by production problems: Last week the laboratory announced that it would be late in delivering half of the orders made by the European Union.
AstraZeneca is also developing an antibody treatment for covid-19, which is in the final stages of testing in various parts of the world. .
The US government has funded the development of this drug and the group plans to supply up to 700,000 doses to the United States this year.